Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Asset Writedowns and Impairment (2024 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with -$539000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment fell 549.17% to -$539000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $280000.0, a 66.51% decrease, with the full-year FY2025 number at $280000.0, down 66.51% from a year prior.
  • Asset Writedowns and Impairment was -$539000.0 for Q4 2025 at Phathom Pharmaceuticals, down from -$80000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $899000.0 in Q1 2025 to a low of -$539000.0 in Q4 2025.